ReviewFrontiers in chemistry2026
Metal-polyphenol nanomedicines for malignant tumor therapy.
Review in Frontiers in chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant tumor is still one of the most critical diseases in clinic. Current therapeutic strategies include surgery, chemoradiotherapy, targeted therapy, and immunotherapy. Nevertheless, the development of novel drugs with superior efficacy and reduced drug toxicity remains a goal for researchers. The rise of nanomedicine has injected new momentum into oncology treatment. Among nano-platforms, metal-polyphenol materials can be engineered into nanodots, nanospheres or network structures, which can encapsulate or load metabolic enzyme inhibitors and chemotherapeutics, enabling precision therapy through both passive and active targeting. Furthermore, these metal-polyphenol nanocomposites frequently integrate the functionalities of chemodynamic therapy, photothermal therapy and photodynamic therapy, synergistically amplifying antitumor effects. To date, however, curcumin, tannic acid, and epigallocatechin gallate have dominated the metal-polyphenol nanomaterials, whereas complex metal-polyphenol nanomaterials remain scarce. Accordingly, this review systematically summarizes the advantages and mechanisms of metal-polyphenol systems categorized by metal species, dissects the antitumor mechanisms of polyphenols, and outlines the substantial potential of metal-polyphenol nanomaterials for treating malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.